Trial · NCT04347720
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Failure of primary pharmacotherapy | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | Receipt of further medical and/or surgical/interventional treatment following an initial course of pharmacotherapy |
| Secondary | Receipt of 2nd course of pharmacotherapy | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | |
| Secondary | Surgical/interventional PDA closure | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | |
| Secondary | Chronic lung disease | birth through 36 weeks post menstrual age | Oxygen or respiratory support requirement at 36 weeks' postmenstrual age or at discharge |
| Secondary | Necrotizing enterocolitis | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | Stage 2 or greater as per Bell's criteria |
| Secondary | Severe intraventricular hemorrhage | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | Grade III-IV according to Papile Criteria |
| Secondary | Definite sepsis | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | Clinical symptoms and signs of sepsis and a positive bacterial culture in a specimen obtained from normally sterile fluids or tissue obtained at postmortem |
| Secondary | Acute Kidney Injury | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | Stage 1 or greater according to the Neonatal AKI KDIGO classification |
| Secondary | Post-treatment serum bilirubin | within 7 days of initiation of pharmacotherapy | |
| Secondary | Maximum serum AST and ALT (u/L) during treatment or within 1 week of treatment completion | within 7 days of completion of pharmacotherapy | |
| Secondary | All-cause mortality during hospital stay | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04347720/registered